153 related articles for article (PubMed ID: 36548103)
21. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
[TBL] [Abstract][Full Text] [Related]
22. Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms.
Ge TJ; Vetter J; Lai HH
Urology; 2017 Nov; 109():67-73. PubMed ID: 28826875
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
Nik-Ahd F; Lenore Ackerman A; Anger J
Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
[TBL] [Abstract][Full Text] [Related]
24. Naturalistic Bladder Filling Reveals Subtypes in Overactive Bladder Syndrome That Differentially Engages Urinary Urgency-Related Brain Circuits: Results From the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN).
Mawla I; Schrepf A; Kutch JJ; Helmuth ME; Smith AR; Ichesco E; Yang CC; Andreev VP; Kreder KJ; Bradley CS; Magnotta VA; Kirkali Z; Harris RE; Lai HH; Harte SE
J Urol; 2024 Jan; 211(1):111-123. PubMed ID: 37796776
[TBL] [Abstract][Full Text] [Related]
25. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study.
Przydacz M; Golabek T; Dudek P; Lipinski M; Chlosta P
Sci Rep; 2020 Nov; 10(1):19819. PubMed ID: 33188254
[TBL] [Abstract][Full Text] [Related]
27. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
28. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.
Lee D; Koo KC; Yoo JW; Lee KS
Low Urin Tract Symptoms; 2022 Jan; 14(1):35-40. PubMed ID: 34323012
[TBL] [Abstract][Full Text] [Related]
29. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
30. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.
Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T
Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392
[TBL] [Abstract][Full Text] [Related]
31. Fluid intake behavior in women with refractory overactive bladder undergoing third line therapy.
Zhao K; Harandi AA; Ramgopal J; Kim J; Weissbart S
Neurourol Urodyn; 2024 Jan; 43(1):44-51. PubMed ID: 37961997
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
Yüce T; Dökmeci F; Çetinkaya ŞE
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
[TBL] [Abstract][Full Text] [Related]
33. Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
Staskin D; Frankel J; Varano S; Kennelly M; Newman DK; Rosenberg MT; Shortino DD; Jankowich RA; Mudd PN
Int J Clin Pract; 2022; 2022():6475014. PubMed ID: 35685566
[TBL] [Abstract][Full Text] [Related]
34. Outcome of coexistent overactive bladder symptoms in women with urodynamic urinary incontinence following anti-incontinence surgery.
Liang CC; Hsieh WC; Huang L
Int Urogynecol J; 2017 Apr; 28(4):605-611. PubMed ID: 27678141
[TBL] [Abstract][Full Text] [Related]
35. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
36. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
37. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
38. A population-based survey of lower urinary tract symptoms (LUTS) and symptom-specific bother: results from the Brazilian LUTS epidemiology study (BLUES).
Moreira ED; Neves RC; Neto AF; Duarte FG; Moreira TL; Lobo CF; Glasser DB
World J Urol; 2013 Dec; 31(6):1451-8. PubMed ID: 23515960
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL.
Coyne KS; Sexton CC; Bell JA; Thompson CL; Dmochowski R; Bavendam T; Chen CI; Quentin Clemens J
Neurourol Urodyn; 2013 Mar; 32(3):230-7. PubMed ID: 22847394
[TBL] [Abstract][Full Text] [Related]
40. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
